AlphaMeld Corporation
Mansi Joshi is an accomplished business development professional with extensive experience in the biotechnology and life sciences sectors. Since October 2017, Mansi has held various leadership roles at InveniAI, currently serving as Vice President of Business Development & Alliances, following positions as Director, Assistant Director, Senior Manager, and Manager in the same field. Prior to this, Mansi worked at LG Life Sciences as Deputy Manager of Business Development & Licensing, and at Premas Biotech as Deputy Manager and Business Development Associate. Early career experiences include a role as Assistant Manager of Business Development at RNA Life Sciences. Mansi holds a Master of Science in Biotechnology from St. Xavier's College, a Post Graduate Diploma in Management with a concentration in Marketing from the Institute of Management Technology, Ghaziabad, and a Bachelor of Science in Biotechnology from the University of Mumbai.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.